ERBB2 and breast carcinoma: First, major survival improvements were achieved in HER2-positive breast cancer with the use of monoclonal antibodies targeting HER2, such as trastuzumab, pertuzumab and trastuzumab emtansine [28,29,30], and their mechanisms of action may at least partially involve the immune system.